Institut Pasteur Files Malaria Pre-Erythrocytic Antigen Patent
Summary
Institut Pasteur filed patent application US20260108591A1 on December 12, 2025, covering chimeric Plasmodium antigenic polypeptides derived from pre-erythrocytic (PE) antigens. The fusion polypeptides are designed to elicit protective immune responses against malaria parasites in human hosts. Inventors include Rogerio Amino, Pierre Charneau, Catherine Blanc, and Vanessa Lagal. The application claims vaccine candidate compositions for human administration.
“The invention relates to chimeric Plasmodium antigenic polypeptides derived from pre-erythrocytic (PE) antigens and associated in a fusion polypeptide.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
Institut Pasteur filed patent application US20260108591A1 for chimeric Plasmodium antigenic polypeptides derived from pre-erythrocytic (PE) antigens, associated in a fusion polypeptide format. The application covers antigenic fusion polypeptides exhibiting protective effects against malaria parasite challenge, particularly targeting Plasmodium sporozoites or achieving sterile immunity. The claimed compositions are suitable as active ingredients for vaccine candidates in human hosts.
Parties engaged in malaria vaccine research or development should monitor this filing for freedom-to-operate considerations. The patent's broad claim scope covering fusion polypeptides derived from pre-erythrocytic antigens may affect competing vaccine development programs targeting the same immunological pathways.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Malaria pre-erythrocytic antigens as a fusion polypeptide and their use in the elicitation of a protective immune response in a host
Application US20260108591A1 Kind: A1 Apr 23, 2026
Assignee
INSTITUT PASTEUR
Inventors
Rogerio AMINO, Pierre CHARNEAU, Catherine BLANC, Vanessa LAGAL
Abstract
The invention relates to chimeric Plasmodium antigenic polypeptides derived from pre-erythrocytic (PE) antigens and associated in a fusion polypeptide. In particular, the invention relates to antigenic fusion polypeptides of malaria parasites wherein said antigenic polypeptides exhibit a protective effect, especially that of eliciting a protective immune response in a host against challenge by Plasmodium sporozoites or a sterile response. Such identified antigenic fusion polypeptides may thus constitute active ingredients suitable for the design of a vaccine candidate, in particular a vaccine suitable for a human host.
CPC Classifications
A61K 39/015 C07K 14/445 C12N 15/86 C07K 2319/00 C12N 2740/15034
Filing Date
2025-12-12
Application No.
19418144
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.